About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 23rd, 2015

The QualityStocks
Daily Stock List


Boston Therapeutics, Inc. (BTHE)

RedChip, TaglichBrothers, and Stock News Now reported on Boston Therapeutics, Inc. (BTHE), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline centers on developing and commercializing therapeutic molecules, which address diabetes and inflammatory diseases. Additionally, the Company developed and markets SUGARDOWN®. This is a non-systemic complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose. Boston Therapeutics has its headquarters in Manchester, New Hampshire.

Its product pipeline includes BTI-320. This is a non-systemic chewable complex carbohydrate-based compound. The design of it is to reduce post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. It is to be taken before meals. BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, decreasing the availability of glucose for absorption into the bloodstream.

Boston Therapeutics has entered into a clinical trial agreement with Joslin Diabetes Center to be the lead clinic in a Phase II study of BTI-320. Moreover, the Company’s product pipeline includes IPOXYN. This is an injectable anti-necrosis drug. The design of it initially is to treat lower limb ischemia associated with diabetes.

Boston Therapeutics announced earlier this year that its affiliate, Advance Pharmaceutical, initiated the SUGARDOWN® clinical trial in Hong Kong. Advance Pharmaceutical will evaluate the effect of SUGARDOWN® on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes. Dr. Andria Luk and Dr. Juliana CN Chan, PRCP are the lead principal investigators. The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong (CUHK), Prince of Wales Hospital.

Boston Therapeutics announced in September 2015 that Advance Pharmaceutical is conducting the aforementioned clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 56 of the planned 60 pre-diabetic patients. Furthermore, the interim clinical analysis in the proof of concept trial demonstrate up to 77 percent reduction in Glucose and up to 27 percent in Fructose.

Last month, Boston Therapeutics reported its financial results for Q3 and nine months ended September 30, 2015 and provided a corporate update.  Mr. David Platt, Ph.D., Boston Therapeutics’ CEO, said, "We have progressed the development of our lead therapeutic candidate, BTI-320, through our alliance partners. The process of initiating a clinical trial with Joslin Diabetes Clinic as the lead site with others is tied to the timing of a capital raise to fund this effort. Our strategic partner, Advance Pharmaceutical Company, Ltd., (APC), based in Hong Kong, has recently completed enrollment in a clinical trial for BTI-320 with Chinese University Hong Kong as a proof of concept for drug effect and clinical benefit.”

Boston Therapeutics, Inc. (BTHE), closed Wednesday's trading session at $0.167, up 45.22%, on 71,041 volume with 10 trades. The average volume for the last 60 days is 74,539 and the stock's 52-week low/high is $0.025/$0.70.

ImmuDyne, Inc. (IMMD)

PennyStocks24, Buzz Stocks, Planet Penny Stocks, Penny Pick Finders, SecretStockPromo, PennyStockProphet, and StockOnion reported previously on ImmuDyne, Inc. (IMMD), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1987, ImmuDyne, Inc. is a health, wellness and skincare company. It is commercializing a portfolio of proprietary topical and orally delivered products, which rely on ImmuDyne’s patented and pure Yeast Beta Glucan ingredients. The Company has developed proprietary topical and oral delivery technologies, with several new market opportunities. ImmuDyne also manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. ImmuDyne has offices in Mt. Kisco, New York; Tampa, Florida; and Florence, Kentucky.

Fundamentally, ImmuDyne’s strategy is to create new market spaces within the wellness industry through the launch of clinically researched, doctor recommended immune support products and services. The Company sells its products directly to consumers, and also to pharmaceutical, nutraceutical, and consumer product companies.

Via a highly complex, proprietary process that employs best-in-class technology, ImmuDyne can extract highly purified beta-1,3/1,6-D-glucan from the cell walls of Saccaharomyces cerevisiae. The Company says that it is well-established in the scientific community that beta-glucans are powerful activators of the innate immune response. Recent studies indicate that yeast beta-1,3/1,6-D-glucans can also activate adaptive immune responses.

ImmuDyne’s products include iNR Wellness™. iNR Wellness is a nutritional supplement. It naturally supports the immune system with PURACERE™ and a vitamin C complex. In addition, products include iNR Wellness MD. This is a nutritional supplement. It naturally empowers one’s immune system with PURACERE™, IP-6, and a vitamin C complex.

Furthermore, ImmuDyne’s product line-up includes iNR Strength™. iNR Strength is a nutritional supplement. It naturally supports the immune system with PURACERE™ and antioxidants. Furthermore, the Company has its ImmuDyne Skin Care Essentials™. Skin Care Essentials ™ is a patented two-step advanced skin care treatment. It contains the unique natural ingredient Beta-1,3/1,6-D-glucan.

This past October, ImmuDyne announced that it entered into a semi-exclusive marketing agreement with Innate Scientific, LLC. This is to launch a complete skin care regime that will be based chiefly on strategic ingredients provided by ImmuDyne. Innate Skincare’s founders have agreed to provide up to $2,000,000 in non-dilutive capital to finance direct marketing initiatives. Innate Scientific’s leadership team has extensive experience in the direct marketing space and a notable record of accomplishment creating national brands expeditiously and profitably.   

ImmuDyne, Inc. (IMMD), closed Wednesday's trading session at $0.14, up 17.15%, on 8,100 volume with 3 trades. The average volume for the last 60 days is 10,089 and the stock's 52-week low/high is $0.03/$0.23.

Rejuvel Bio-Sciences, Inc. (NUUU)

Wall Street Corner, Innovative Marketing, and SmallCapVoice reported on Rejuvel Bio-Sciences, Inc. (NUUU), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Rejuvel Bio-Sciences, Inc. is a NASA Technology Transfer Partner and the creator of REJUVEL 3D Ageless Infinity Microgravity Cell Renewal Cream. The Company is the parent firm of Rejuvel Int’l, Inc. It has created REJUVEL 3D which is based on technology developed by NASA to grow cells in an environment that imitates the near weightlessness of space.

Rejuvel Bio-Sciences’ shares trade on the OTC Bulletin Board. Founded in 2009, the Company has its headquarters in Miami, Florida. Rejuvel Bio-Sciences, Inc. is formerly Technology Applications International Corporation, and Rejuvel Int’l, Inc. is formerly Renuell Int’l, Inc.

REJUVEL 3D is the first ever three-dimensional (3D) skin renewal system using NASA patented technology, exclusively licensed from the National Aeronautics and Space Administration and Administrators of the Tulane Educational Fund. This technology permits REJUVEL 3D to be produced with an ingredient that has anti-aging properties found in no other product.

REJUVEL 3D is recognized by The Space Foundation as a Space-Certified Product, which has been created as a direct result of space technology. The technology employed to make Rejuvel Bio-Sciences’ products have been inducted into the Space Technology Hall of Fame.

The Company indicates that the benefits of REJUVEL 3D products start with a bioreactor, developed by NASA scientists and engineers. The bioreactor produces a suspended microgravity environment through utilizing a rotating vessel to grow cell cultures. It said that experts found that this stress-free environment permitted the cell cultures to grow in a three-dimensional state, much like how cells grow in the human body.

These cells are more equivalent to natural skin cells. Additionally, they were exposed to an increased amount of nutrients and functioned in a more complete manner. The results uncovered a significant skincare breakthrough versus normally utilized two-dimensional methods that force the cells to grow in a restrictive area, leaving them deformed and poorly functioning.

Recently, Rejuvel Bio-Sciences announced that the Chairman of its Advisory Board, Mr. Jacob G. Appelbaum, Ph.D., wrote a column describing the ground-breaking science behind Rejuvel 3D. Dr. Appelbaum recounts in the article how he and an old friend and business colleague, Mr. Charles Scimeca, became fascinated by work at NASA growing cells in three dimensions using a rotating bioreactor that imitates the microgravity of space.

Rejuvel Bio-Sciences, Inc. (NUUU), closed Wednesday's trading session at $0.022, up 76.00%, on 40,100 volume with 3 trades. The average volume for the last 60 days is 79,223 and the stock's 52-week low/high is $0.012/$1.00.

Sterling Consolidated Corp. (STCC)

PennyStocks24, Pumps and Dumps, Value Penny Stocks, and HotStockProfits reported previously on Sterling Consolidated Corp. (STCC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Sterling Consolidated Corp., by way of its subsidiary, Sterling Seal and Supply Inc., distributes and sells O-rings and other rubber products around the world. The Company previously went by the name Oceanview Acquisition Corp. It changed its corporate name to Sterling Consolidated Corp. in May of 2012. Sterling Consolidated has its head office in Neptune, New Jersey.

Sterling incorporated in the State of Nevada as the above-mentioned Oceanview Acquisition Corp. on January 31, 2011. On May 18, 2012, the Company amended its Articles of Incorporation to change its name to Sterling Consolidated Corp. Its largest subsidiary is Sterling Seal & Supply, Inc., which is a New Jersey corporation that was incorporated in 1997.

Sterling Consolidated provides O-rings, rubber seals, oil seals, custom molded rubber parts, custom Teflon parts, Teflon rods, O-ring cords, bonded seals, O-ring kits, as well as stuffing box sealant products. These are for use in automotive, pump, transmissions, oil and energy, machinery, and packaging industries. The Company sells its products directly to smaller distributors and original equipment manufacturers (OEMs). In addition, it also engages in the rental of commercial space to third parties.

Sterling Consolidated owns real property via its subsidiaries ADDR Properties, LLC (ADDR) and Q5 Ventures, LLC (Q5). ADDR owns a 28,000 square foot facility in Neptune, New Jersey. It is mainly used by Sterling Seal for its operations. Moreover, ADDR owns another property in Cliffwood Beach, New Jersey. It was formerly occupied by Sterling Seal; it is now rented out to tenants. Q5 owns a 5,000 square foot facility that is used by Sterling Seal in Florida.

Furthermore, Sterling Consolidated’s subsidiary, Integrity Cargo Freight Corporation, is a freight forwarding business. Integrity shares a facility with Sterling Seal. It manages the importation of Sterling Seal's products and exports products for Sterling Seal to different countries. At present, 80 percent of Sterling Seal's imports come from Asia, and 10 percent of its sales are exported to various countries. Nonetheless, the Company states that all payables are billed and collected in U.S. Dollars, so Sterling Consolidated does not bear any foreign exchange risk on open payables.

Sterling Consolidated Corp. (STCC), closed Wednesday's trading session at $0.0195, up 62.50%, on 8,000 volume with 1 trade. The average volume for the last 60 days is 15,220 and the stock's 52-week low/high is $0.012/$0.065.

Xenonics Holdings, Inc. (XNNH)

TopPennyStockMovers, PennyStocks24, Bull Trends, and Club Penny Stocks Network reported earlier on Xenonics Holdings, Inc. (XNNH), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Xenonics Holdings, Inc. develops and produces advanced, lightweight, and compact ultra-high-intensity illumination and low-light vision products. These products are for military, law enforcement, public safety, and also private sector and commercial applications. The Company uses patented technologies. It provides unique solutions for customers who must see farther so they can do their jobs safer and also better. Xenonics Holdings is based in Carlsbad, California.

The Company’s illumination engine delivers tightly focused, ultra-high intensity beams of visible or infrared light (and also ultraviolet). In addition, Xenonics’ technology produces a beam without the "black hole", which is characteristic of other illumination products.

Xenonics' NightHunter line of illumination products is used by every branch of the U.S. Armed Forces. This line is also used by law enforcement and security agencies. NightHunters provide innovative capabilities that enable users to see first and act first, with the versatility to quickly adapt to and dominate changing conditions at night.

The NightHunter line of products consists of the NightHunterONE, NightHunter3, and the NightHunterext. The NightHunter® is the world’s longest-range and most versatile compact illumination system that allows a user to see more than a mile away. The NightHunter® can be used on foot, from vehicles, boats, and helicopters or fixed mounted.

The design of Xenonics’ SuperVision high-definition night vision is for commercial and military applications. SuperVision’s performance compares to military-grade (Gen III) night vision. It provides greater resolution, better clarity, and longer range and zoom capability.

SuperVision’s patented digital technology provides a 2x to 8x zoom magnification, high resolution HDTV display, and proprietary DSP technology. SuperVision is especially designed for military, law enforcement, and security professionals and their special requirements in the dangerous global environment.

Market applications for Xenonics products include Force Protection; Physical Security; Peacekeeping; Reconnaissance; Target Designation; Search & Rescue; Close Air Support; and Surveillance. In addition, they include Explosive Detection; Perimeter Security; Harbor Security; Infrastructure Security; Crowd/Riot Control; Detection; Counter-Measure; and Tactical. Furthermore, they include Interdiction; Border Security; Fugitive Apprehension; High Risk Warrant Service; Crime Scene; Corrections; as well as Game/Animal Scouting.

Xenonics Holdings, Inc. (XNNH), closed Wednesday's trading session at $0.0699, up 39.80%, on 500 volume with 1 trade. The average volume for the last 60 days is 32,989 and the stock's 52-week low/high is $0.0401/$0.47.


The QualityStocks
Company Corner


International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $3.60, up 2.56%, on 37,860 volume with 96 trades. The stock’s average daily volume over the past 60 days is 17,726, and its 52-week low/high is $1.25/$11.625.

International Stem Cell Corp. a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. The Florey is one of the world's leading brain research centers, employing the largest neuroscience research team in Australia.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products

Oakridge Global Energy Solutions, Inc. (OGES)

The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.85, up 25.00%, on 67,197 volume with 46 trades. The stock’s average daily volume over the past 60 days is 20,475, and its 52-week low/high is $0.15/$2.40.

Oakridge Global Energy Solutions, Inc. (OGES) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market. Disclaimer

Oakridge Global Energy Solutions, Inc. Company Blog

Oakridge Global Energy Solutions, Inc. News:

Oakridge Global Energy Solutions to Be Highlighted on FOX Business Network’s “New To The Street”

Oakridge Global Energy Solutions Announces Q3 Results

Oakridge Global Energy Solutions to Be Showcased In Upcoming “New To The Street” Series

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.05, up 8.46%, on 1,642,179 volume with 60 trades. The stock’s average daily volume over the past 60 days is 1,904,488 and its 52-week low/high is $0.0035/$0.40.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Signs Financing Agreement With GHS Capital

Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System

Dominovas Energy Acquires Independent Power Producer License From the Angolan Ministry of Petroleum

GTX Corp. (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.0103, up 8.42%, on 507,710 volume with 10 trades. The stock’s average daily volume over the past 60 days is 576,912, and its 52-week low/high is $0.0084/$0.023.

GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.

GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.

The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.

As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.

"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer

GTX Corp. Company Blog

GTX Corp. News:

GTX Corp. Launches New Track My Workforce Mobile App and Tracking Portal

GTX Corp (GTXO) CEO Featured in Exclusive QualityStocks Interview

GTX Corp Reports Third Quarter 2015 Financial Results and Business Overview

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0549, up 4.57%, on 391,480 volume with 16 trades. The stock’s average daily volume over the past 60 days is 217,442, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite

Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251